Ionis Pharmaceuticals
Ionis Pharmaceuticals
IONS
NASDAQ
47.68
USD
36.97%
About
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development.
The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death.
WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 959.1K |
| Three Month Average Volume | 26.7M |
| High Low | |
| Fifty-Two Week High | 54.4446 USD |
| Fifty-Two Week Low | 35.95 USD |
| Fifty-Two Week High Date | 12 Jan 2024 |
| Fifty-Two Week Low Date | 31 May 2024 |
| Price and Volume | |
| Current Price | 47.68 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.14% |
| Thirteen Week Relative Price Change | 18.58% |
| Twenty-Six Week Relative Price Change | -4.61% |
| Fifty-Two Week Relative Price Change | -5.51% |
| Year-to-Date Relative Price Change | -20.41% |
| Price Change | |
| One Day Price Change | -4.45% |
| Thirteen Week Price Change | 26.91% |
| Twenty-Six Week Price Change | 4.88% |
| Five Day Price Change | 1.62% |
| Fifty-Two Week Price Change | 18.40% |
| Year-to-Date Price Change | -5.75% |
| Month-to-Date Price Change | -3.60% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.67898 USD |
| Book Value Per Share (Most Recent Quarter) | 1.80584 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.67898 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.80584 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.29825 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 5.50071 USD |
| Revenue Per Share (Trailing Twelve Months) | 5.62542 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.55804 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.52827 USD |
| Normalized (Last Fiscal Year) | -2.52735 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.55804 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.52827 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.55804 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.52827 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 16.1507 USD |
| Cash Per Share (Most Recent Quarter) | 14.23511 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.46829 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.44174 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.47589 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -7 |
| Cash Flow Revenue (Trailing Twelve Months) | -44 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -43.33% |
| Pretax Margin (Last Fiscal Year) | -42.40% |
| Pretax Margin (5 Year) | -10.33% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 98.84% |
| Gross Margin (Trailing Twelve Months) | 98.58% |
| Gross Margin (5 Year) | 98.75% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -43.21% |
| Operating Margin (Trailing Twelve Months) | -44.61% |
| Operating Margin (5 Year) | -16.58% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -46.50% |
| Net Profit Margin (Trailing Twelve Months) | -44.96% |
| Net Profit Margin (5 Year) | -21.23% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -18.82% |
| Tangible Book Value (5 Year) | -17.70% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 19.55% |
| Revenue Growth (3 Year) | 5.60% |
| Revenue Change (Trailing Twelve Months) | 29.00% |
| Revenue Per Share Growth | 4.22% |
| Revenue Growth (5 Year) | 2.60% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 11.83% |
| Total Debt (5 Year) | 14.52% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 23.83% |
| EPS Change (Trailing Twelve Months) | -16.66% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 18 |
| Price to Tangible Book (Most Recent Quarter) | 26 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -801,889,000 |
| Net Debt (Last Fiscal Year) | -1,057,211,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 9 |
| Price to Sales (Trailing Twelve Months) | 9 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 764 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 36 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 18 |
| Price to Book (Most Recent Quarter) | 26 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 318 |
| Long Term Debt to Equity (Most Recent Quarter) | 467 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 6 |
| Quick Ratio (Most Recent Quarter) | 8 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -331,318,000 |
| Free Cash Flow (Trailing Twelve Months) | -358,024,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 329 |
| Total Debt to Equity (Most Recent Quarter) | 484 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -13.26% |
| Return on Assets (Trailing Twelve Months) | -12.92% |
| Return on Assets (5 Year) | -6.30% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -76.34% |
| Return on Equity (Trailing Twelve Months) | -105.71% |
| Return on Equity (5 Year) | -19.43% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -15.38% |
| Return on Investment (Trailing Twelve Months) | -14.43% |
| Return on Investment (5 Year) | -7.44% |